Zoetis Inc. $ZTS Shares Sold by Stephens Inc. AR

Stephens Inc. AR cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,088 shares of the company’s stock after selling 9,939 shares during the period. Stephens Inc. AR’s holdings in Zoetis were worth $16,242,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. RFG Advisory LLC grew its stake in shares of Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after acquiring an additional 80 shares in the last quarter. YANKCOM Partnership grew its stake in Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares in the last quarter. Evergreen Capital Management LLC grew its stake in Zoetis by 3.3% in the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after purchasing an additional 85 shares in the last quarter. Beese Fulmer Investment Management Inc. grew its stake in Zoetis by 2.4% in the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares in the last quarter. Finally, Quest 10 Wealth Builders Inc. grew its stake in Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on ZTS shares. Citigroup started coverage on Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target for the company. UBS Group decreased their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $105.00 price target on Zoetis in a research note on Friday, May 8th. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research note on Friday. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $137.50.

Zoetis Stock Performance

Shares of ZTS stock opened at $74.11 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business has a 50 day moving average of $112.28 and a two-hundred day moving average of $120.94. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $172.23. The company has a market cap of $31.07 billion, a P/E ratio of 12.29, a PEG ratio of 1.23 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.89 EPS for the current year.

Insider Activity

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.